Abstract: This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula I, II or any of Compounds 100-128 or any of those in Tables 2 or 3) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.

Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g., HDAC2).

Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g., HDAC2).

Abstract: A shoulder implant system includes a humeral stem implant, a humeral neck implant component, a humeral head implant component, and a glenoid implant. The humeral stem implant has a fin coupled to an exterior surface thereof that is inwardly tapered at an angle relative to vertical. At least a portion of the fin forms a wedge that directly engages and compacts cancellous bone during installation of the humeral stem implant. The humeral neck implant component is configured to be coupled with the humeral stem implant. The humeral head implant component is configured to be coupled to the humeral stem implant via the humeral neck implant component. The glenoid implant has a plurality of peripheral pegs. Each of the peripheral pegs has a plurality of sets of resilient lobes.

Abstract: A shoulder implant system includes a humeral stem implant, a humeral neck implant component, a humeral head implant component, and a glenoid implant. The humeral stem implant has a fin coupled to an exterior surface thereof that is inwardly tapered at an angle relative to vertical. At least a portion of the fin forms a wedge that directly engages and compacts cancellous bone during installation of the humeral stem implant. The humeral neck implant component is configured to be coupled with the humeral stem implant. The humeral head implant component is configured to be coupled to the humeral stem implant via the humeral neck implant component. The glenoid implant has a plurality of peripheral pegs. Each of the peripheral pegs has a plurality of sets of resilient lobes.

Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g., HDAC2).

Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g. HDAC2).

Abstract: In an aspect of the disclosure, a method, a computer-readable medium, and an apparatus of adjusting color palettes for a display device based on ambient light levels are provided. The apparatus determines a first ambient light level based at least in part on first information received from one or more sensors. A first color palette associated with the first ambient light level is generated. The apparatus determines a first screen brightness level associated with the first ambient light level and displays a first image on a display screen using the first color palette and the first screen brightness level.

Abstract: In an aspect of the disclosure, a method, a computer-readable medium, and an apparatus of adjusting color palettes for a display device based on ambient light levels are provided. The apparatus determines a first ambient light level based at least in part on first information received from one or more sensors. A first color palette associated with the first ambient light level is generated. The apparatus determines a first screen brightness level associated with the first ambient light level and displays a first image on a display screen using the first color palette and the first screen brightness level.

Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g., HDAC2).

Abstract: A shoulder implant system includes a humeral stem implant, a humeral neck implant component, a humeral head implant component, and a glenoid implant. The humeral stem implant has a fin coupled to an exterior surface thereof that is inwardly tapered at an angle relative to vertical. At least a portion of the fin forms a wedge that directly engages and compacts cancellous bone during installation of the humeral stem implant. The humeral neck implant component is configured to be coupled with the humeral stem implant. The humeral head implant component is configured to be coupled to the humeral stem implant via the humeral neck implant component. The glenoid implant has a plurality of peripheral pegs. Each of the peripheral pegs has a plurality of sets of resilient lobes.

Abstract: This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula I, II or any of Compounds 100-128 or any of those in Tables 2 or 3) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.

Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g., HDAC2).

Abstract: A system and method for measuring the liquid level in a tank or container is provided. The system can have a sensor string comprising a plurality of analog output hall-effect sensors and a computer readable memory containing sensor string information, a float having a magnetic field and positionable relative to the sensor string, and a controller containing at least one processing unit, at least one memory and a sensor string interface for connecting the controller to the sensor string. The system can be operative to obtain the sensor string information from the at least one memory of the sensor string, obtain a preloaded waveform indicating the output of a sensor relative to the position of the float and approximate the position of the float relative to the sensor string using the normalized output of at least one of the sensors and the preloaded waveform.

Abstract: Adaptive de-noise filtering of signals is disclosed. A signal may be identified and a noise level corresponding to noise associated with the signal may be determined. The noise level may be determined by isolating the noise from the signal and generating a metric indicative of the noise level. A threshold noise level may be identified. A cutoff frequency may be determined based at least in part on the noise level and the threshold noise level, and, optionally, based on one or more characteristics associated with a low pass filter. The signal may be low pass filtered based at least in part on the cutoff frequency to generate a filtered signal. Additional signals may be identified and filtered in accordance with respective corresponding cutoff frequencies such that noise levels associated with the additional filtered signals and the filtered signal may be substantially the same and at or below the threshold noise level.

Abstract: Described are methods and systems for powering an Otto-cycle engine using gasoline and compressed natural gas (CNG). The Otto-cycle engine can be powered by determining a quantity of the gasoline and a quantity of the CNG to deliver to a cylinder of the engine during an engine cycle such that combustion within the cylinder occurs at a pre-determined air-fuel ratio; delivering the quantity of the gasoline to the cylinder via a gasoline injector and delivering the quantity of the CNG to the cylinder via a CNG injector such that the gasoline and the CNG combust during the same combustion event; and combusting the gasoline and the CNG within the cylinder. Delivering CNG and gasoline to the cylinder using separate injectors allows the quantities of CNG and gasoline to vary in response to engine operating conditions, which allows the fuel mixture to be adjusted to satisfy engine power and emissions criteria.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein Rx is as defined and described herein, compositions thereof, and methods of using the same.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein each of the variables listed above are as defined and described herein, compositions thereof, and methods of using the same.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein Rx is as defined and described herein, compositions thereof, and methods of using the same.